Cite
HARVARD Citation
Zhang, N. et al. (n.d.). 162P Efficacy and safety of GEMOX (gemcitabine plus oxaliplatin) plus sintilimab and bevacizumab as a conversion therapy in patients with initially unresectable biliary tract cancers (BTC): A single-arm, phase II study. Immuno-oncology technology. p. . [Online].